A Sonoma, California, pharmaceutical company is touting its new product, Sonoma Select.
Its a powerful drug that will help treat and prevent brain cancer.
And it could also save lives.
The drug, named Sonoma select, has been used by some doctors for more than a decade.
But it wasn’t until 2016 that it hit the market, after a breakthrough in a drug company called GlaxoSmithKline (GSK).
The drug is known as a glioma treatment and it is designed to stop the spread of brain tumors.
The drug works by blocking the spread and growth of the tumor.
When the drug hits the market today, it will be the first treatment to be approved by the U.S. Food and Drug Administration for gliomas.
The agency will review it for safety and efficacy, and then determine whether it’s safe and effective.
The FDA will review any additional research and recommendations it deems necessary.
The FDA approval is expected to help the company sell the drug to a broader population of patients, including those with brain cancer, and eventually to doctors in the U and Canada.
The company says the drug is designed for those who are diagnosed with glioblastoma, a type of brain cancer that affects about a quarter of the population.
It also targets other types of cancers, including brain cancers in the liver and pancreas, which can cause the death of cells in the pancreases.
The study that led to the FDA approval also involved a team of researchers from the University of California, San Francisco and Columbia University, and was funded by the National Institutes of Health (NIH).
The researchers found that the drug blocks a protein called PDGF-1 from growing in the tumors.
They said it worked by slowing down the growth of a protein that normally acts as a kind of gatekeeper.
The researchers then compared this PDGF inhibitor to a drug that targets the protein and found that they blocked the drug from making tumors bigger.
This was a breakthrough, and so were the results.
It was then that the scientists realized they could use this new drug to treat other types, including cancer in the brain.
And they said that was a great idea because it could be used to treat patients who have had tumors before, and it could then be used in the future to treat tumors in other parts of the body.
They also said it could potentially help reduce the number of patients who need surgery to remove brain tumors, because surgery could cause the tumors to grow again.
It could also help people with the rare disease of B-cell lymphoma, which is a type that causes immune system damage.
The hope is that this could lead to the drug reaching the market by 2025.
The National Institutes for Health is a federally funded research and development organization.
It is part of the National Institute on Aging, which aims to advance human health through research that advances understanding of the causes and treatments of disease.
For more information, visit www.nina.nih.gov/sonoma.